NB3 Stock Overview
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Neurocrine Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$111.90 |
| 52 Week High | US$144.35 |
| 52 Week Low | US$96.00 |
| Beta | 0.36 |
| 11 Month Change | 10.96% |
| 3 Month Change | -17.54% |
| 1 Year Change | 7.44% |
| 33 Year Change | 39.74% |
| 5 Year Change | 10.79% |
| Change since IPO | 266.89% |
Recent News & Updates
Recent updates
Shareholder Returns
| NB3 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 4.5% | 0.8% | -2.2% |
| 1Y | 7.4% | -14.4% | 13.3% |
Return vs Industry: NB3 exceeded the German Biotechs industry which returned -15.4% over the past year.
Return vs Market: NB3 underperformed the German Market which returned 13.6% over the past year.
Price Volatility
| NB3 volatility | |
|---|---|
| NB3 Average Weekly Movement | 6.2% |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: NB3 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: NB3's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 1,700 | Kyle Gano | www.neurocrine.com |
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications.
Neurocrine Biosciences, Inc. Fundamentals Summary
| NB3 fundamental statistics | |
|---|---|
| Market cap | €11.38b |
| Earnings (TTM) | €354.80m |
| Revenue (TTM) | €2.06b |
31.6x
P/E Ratio5.4x
P/S RatioIs NB3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NB3 income statement (TTM) | |
|---|---|
| Revenue | US$2.24b |
| Cost of Revenue | US$716.20m |
| Gross Profit | US$1.53b |
| Other Expenses | US$1.14b |
| Earnings | US$385.90m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.81 |
| Gross Margin | 68.07% |
| Net Profit Margin | 17.21% |
| Debt/Equity Ratio | 0% |
How did NB3 perform over the long term?
See historical performance and comparison